CHINA PHARMA HOLDINGS, INC. (CPHI) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
18/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCPHI / S&P 8.20% / 15.20% |
LoseCPHI / S&P -10.97% / 15.00% |
LoseCPHI / S&P -72.19% / 50.40% |
| 2026-Q10/3 |
LoseCPHI / S&P -49.59% / -4.33% |
LoseCPHI / S&P -7.07% / 11.30% |
LoseCPHI / S&P -75.89% / 27.70% |
| 2025-Q40/3 |
LoseCPHI / S&P -37.95% / 2.65% |
LoseCPHI / S&P -8.49% / 9.00% |
LoseCPHI / S&P -72.79% / 13.40% |
| 2025-Q31/3 |
WinCPHI / S&P 8.94% / 8.12% |
LoseCPHI / S&P -26.92% / 4.61% |
LoseCPHI / S&P -54.82% / 13.45% |
| 2025-Q20/3 |
LoseCPHI / S&P -31.15% / 10.94% |
LoseCPHI / S&P -29.64% / 4.83% |
LoseCPHI / S&P -21.35% / 10.63% |
| 2025-Q12/3 |
WinCPHI / S&P 13.04% / -4.27% |
LoseCPHI / S&P -33.10% / 4.98% |
WinCPHI / S&P 62.32% / 10.57% |
| 2024-Q41/3 |
LoseCPHI / S&P -4.17% / 2.41% |
LoseCPHI / S&P -35.41% / 5.25% |
WinCPHI / S&P 277.78% / 6.15% |
| 2024-Q30/3 |
LoseCPHI / S&P -4.00% / 5.89% |
LoseCPHI / S&P -28.76% / 5.89% |
LoseCPHI / S&P -41.84% / 6.11% |
| 2024-Q20/3 |
LoseCPHI / S&P -32.43% / 4.28% |
LoseCPHI / S&P -21.36% / 5.38% |
LoseCPHI / S&P -49.34% / 5.12% |
| 2024-Q10/3 |
LoseCPHI / S&P -38.33% / 10.56% |
LoseCPHI / S&P -24.11% / 5.71% |
LoseCPHI / S&P -61.88% / 5.59% |
| 2023-Q40/3 |
LoseCPHI / S&P -20.00% / 11.69% |
LoseCPHI / S&P -13.48% / 6.81% |
LoseCPHI / S&P -80.95% / 7.78% |
| 2023-Q31/3 |
LoseCPHI / S&P -55.88% / -3.27% |
LoseCPHI / S&P -3.59% / 7.52% |
WinCPHI / S&P 213.60% / -5.03% |
| 2023-Q21/3 |
LoseCPHI / S&P -12.82% / 8.74% |
LoseCPHI / S&P -1.73% / 9.50% |
WinCPHI / S&P 241.44% / -8.57% |
| 2023-Q11/3 |
LoseCPHI / S&P -61.00% / 7.50% |
LoseCPHI / S&P -4.81% / 10.77% |
WinCPHI / S&P 281.05% / -15.69% |
| 2022-Q40/3 |
LoseCPHI / S&P -23.08% / 7.56% |
LoseCPHI / S&P -15.95% / 11.88% |
LoseCPHI / S&P CPHI unavailable / -17.99% |
| 2022-Q30/3 |
LoseCPHI / S&P -38.10% / -4.88% |
LoseCPHI / S&P -16.64% / 13.47% |
LoseCPHI / S&P CPHI unavailable / -1.41% |
| 2022-Q20/3 |
LoseCPHI / S&P -46.15% / -16.10% |
LoseCPHI / S&P -19.99% / 13.71% |
LoseCPHI / S&P CPHI unavailable / 11.04% |
| 2022-Q10/3 |
LoseCPHI / S&P -18.75% / -4.60% |
LoseCPHI / S&P -22.45% / 15.97% |
LoseCPHI / S&P CPHI unavailable / 42.23% |
| 2021-Q40/3 |
LoseCPHI / S&P -14.29% / 11.03% |
LoseCPHI / S&P -11.27% / 15.00% |
LoseCPHI / S&P CPHI unavailable / 96.40% |
| 2021-Q30/3 |
LoseCPHI / S&P -22.22% / 0.58% |
LoseCPHI / S&P -11.84% / 10.77% |
LoseCPHI / S&P CPHI unavailable / 69.42% |
| 2021-Q20/3 |
LoseCPHI / S&P -14.29% / 8.55% |
LoseCPHI / S&P -7.79% / 6.58% |
LoseCPHI / S&P CPHI unavailable / 51.81% |
| 2021-Q12/3 |
WinCPHI / S&P 86.67% / 6.17% |
WinCPHI / S&P 17.44% / -1.06% |
LoseCPHI / S&P CPHI unavailable / 7.39% |
| 2020-Q42/3 |
WinCPHI / S&P 25.00% / 12.15% |
WinCPHI / S&P -0.53% / -3.72% |
LoseCPHI / S&P CPHI unavailable / -33.42% |
| 2020-Q31/3 |
LoseCPHI / S&P -46.27% / 8.93% |
WinCPHI / S&P -1.21% / -2.04% |
LoseCPHI / S&P CPHI unavailable / -27.10% |
| 2020-Q21/3 |
WinCPHI / S&P 34.00% / 20.54% |
LoseCPHI / S&P -0.73% / -0.46% |
LoseCPHI / S&P CPHI unavailable / -27.11% |
| 2020-Q11/3 |
WinCPHI / S&P 108.33% / -19.60% |
LoseCPHI / S&P -16.19% / 3.47% |
LoseCPHI / S&P CPHI unavailable / -14.75% |
| 2019-Q40/3 |
LoseCPHI / S&P -4.00% / 9.07% |
LoseCPHI / S&P -11.41% / 5.36% |
LoseCPHI / S&P CPHI unavailable / 2.99% |
| 2019-Q30/3 |
LoseCPHI / S&P -21.88% / 1.70% |
LoseCPHI / S&P -14.05% / 5.02% |
LoseCPHI / S&P CPHI unavailable / 0.21% |
| 2019-Q20/3 |
LoseCPHI / S&P -3.03% / 4.30% |
LoseCPHI / S&P -20.00% / 6.64% |
LoseCPHI / S&P CPHI unavailable / 8.65% |
| 2019-Q11/3 |
WinCPHI / S&P 26.92% / 13.65% |
LoseCPHI / S&P -14.02% / 8.12% |
LoseCPHI / S&P CPHI unavailable / 14.29% |
| 2018-Q41/3 |
WinCPHI / S&P 30.00% / -13.52% |
LoseCPHI / S&P -6.67% / 9.05% |
LoseCPHI / S&P CPHI unavailable / 18.23% |
| 2018-Q30/3 |
LoseCPHI / S&P -9.09% / 7.71% |
LoseCPHI / S&P -11.56% / 10.21% |
LoseCPHI / S&P CPHI unavailable / 19.06% |
| 2018-Q20/3 |
LoseCPHI / S&P -31.25% / 3.43% |
LoseCPHI / S&P -5.42% / 9.03% |
LoseCPHI / S&P CPHI unavailable / 14.46% |
| 2018-Q11/3 |
WinCPHI / S&P 77.78% / -0.76% |
LoseCPHI / S&P -10.99% / 7.68% |
LoseCPHI / S&P CPHI unavailable / 12.46% |
| 2017-Q40/3 |
LoseCPHI / S&P 0.00% / 6.64% |
LoseCPHI / S&P -15.15% / 7.03% |
LoseCPHI / S&P CPHI unavailable / 13.82% |
| 2017-Q30/3 |
LoseCPHI / S&P -21.74% / 4.48% |
LoseCPHI / S&P -1.25% / 5.68% |
LoseCPHI / S&P CPHI unavailable / 17.57% |
| 2017-Q20/3 |
LoseCPHI / S&P -11.54% / 3.09% |
LoseCPHI / S&P -9.74% / 4.83% |
LoseCPHI / S&P CPHI unavailable / 17.74% |
| 2017-Q10/3 |
LoseCPHI / S&P 0.00% / 6.07% |
LoseCPHI / S&P -16.84% / 3.67% |
LoseCPHI / S&P CPHI unavailable / 13.32% |
| 2016-Q41/3 |
WinCPHI / S&P 18.18% / 3.82% |
LoseCPHI / S&P -23.49% / 2.09% |
LoseCPHI / S&P CPHI unavailable / 7.05% |
| 2016-Q30/3 |
LoseCPHI / S&P -8.33% / 3.85% |
LoseCPHI / S&P -22.77% / 0.20% |
LoseCPHI / S&P -44.00% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CPHI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -35.97% | 20.78% |
| Annualized return | -35.97% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CPHI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.74% | 83.14% |
| Annualized return | -69.64% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CPHI total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.32% | 319.30% |
| Annualized return | -39.25% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |